Piperidine and azepine derivatives as prokineticin receptor modulators
First Claim
Patent Images
1. A pharmaceutical composition comprising a compound selected from the group consisting of:
- racemic 5-{[3-(4-Chloro-2-methylphenyl)piperidin-1-yl]carbonyl}-N-methylpyridazin-3-amine;
a mixture of R and S enantiomers of 5-{[3-(4-Chloro-2-methylphenyl)piperidin-1-yl]carbonyl}-N-methylpyridazin-3-amine;
5-{[(3R)-3-(4-Chloro-2-methylphenyl)piperidin-1-yl]carbonyl}-N-methylpyridazin-3-amine;
racemic 4-({3-[4-Chloro-2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)-1-methyl-1H-pyrazol-3-amine;
a mixture of R and S enantiomers of 4-({3-[4-Chloro-2-(trifluoromethyl)phenyl]piperidin-1-yl} carbonyl)-1-methyl-1H-pyrazol-3-amine;
4-({(3R)-3-[4-Chloro-2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)-1-methyl-1H-pyrazol-3-amine;
4-({(3S)-3-[4-Chloro-2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)-1-methyl-1H-pyrazol-3-amine; and
pharmaceutically acceptable salts thereof,in association with a pharmaceutically acceptable adjuvant, diluent or carrier, and optionally one or more other therapeutic agents.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, X, R1, R2, R3 and R5 are as defined in the specification, processes for their preparation, pharmaceutical compositions N containing them and their use in therapy.
-
Citations
32 Claims
-
1. A pharmaceutical composition comprising a compound selected from the group consisting of:
-
racemic 5-{[3-(4-Chloro-2-methylphenyl)piperidin-1-yl]carbonyl}-N-methylpyridazin-3-amine; a mixture of R and S enantiomers of 5-{[3-(4-Chloro-2-methylphenyl)piperidin-1-yl]carbonyl}-N-methylpyridazin-3-amine; 5-{[(3R)-3-(4-Chloro-2-methylphenyl)piperidin-1-yl]carbonyl}-N-methylpyridazin-3-amine; racemic 4-({3-[4-Chloro-2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)-1-methyl-1H-pyrazol-3-amine; a mixture of R and S enantiomers of 4-({3-[4-Chloro-2-(trifluoromethyl)phenyl]piperidin-1-yl} carbonyl)-1-methyl-1H-pyrazol-3-amine; 4-({(3R)-3-[4-Chloro-2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)-1-methyl-1H-pyrazol-3-amine; 4-({(3S)-3-[4-Chloro-2-(trifluoromethyl)phenyl]piperidin-1-yl}carbonyl)-1-methyl-1H-pyrazol-3-amine; and pharmaceutically acceptable salts thereof, in association with a pharmaceutically acceptable adjuvant, diluent or carrier, and optionally one or more other therapeutic agents. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)
-
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeTakeda Pharmaceutical Company Limited
-
Original AssigneeTakeda Pharmaceutical Company Limited
-
InventorsBousba, Sarah, Goldby, Anne, Jenkins, Kerry, Kinsella, Natasha, Teall, Martin
-
Primary Examiner(s)Coleman, Brenda L
-
Application NumberUS15/702,100Publication NumberTime in Patent Office469 DaysField of SearchUS Class CurrentCPC Class CodesA61K 31/454 containing a five-membered ...A61K 31/4545 containing a six-membered r...A61K 31/501 not condensed and containin...A61K 31/55 having seven-membered rings...A61P 1/00 Drugs for disorders of the ...A61P 25/04 Centrally acting analgesics...A61P 25/18 Antipsychotics, i.e. neurol...A61P 25/28 for treating neurodegenerat...A61P 43/00 Drugs for specific purposes...C07D 401/06 linked by a carbon chain co...C07D 401/14 containing three or more he...C07D 403/06 linked by a carbon chain co...
